← FDA DRUG APPROVALS

FDA ANDA · ANDA076313

OCTREOTIDE ACETATE

Sponsor: WEST-WARD PHARMS INT

APPLICATION
ANDA076313
TYPE
ANDA
ORIGINAL APPROVAL
2005-03-28
LATEST ACTION
2022-09-16
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OCTREOTIDE ACETATE (PRESERVATIVE FREE)Prescription
OCTREOTIDE ACETATE EQ 0.5MG BASE/ML · INJECTABLE · INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)Prescription
OCTREOTIDE ACETATE EQ 0.1MG BASE/ML · INJECTABLE · INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)Prescription
OCTREOTIDE ACETATE EQ 0.05MG BASE/ML · INJECTABLE · INJECTION

Approval history

2022-09-16Labeling · Supplement 19 · standardAP
2022-09-16Labeling · Supplement 21 · standardAP
2022-09-16Labeling · Supplement 16 · standardAP
2018-08-27Manufacturing (CMC) · Supplement 13 · unknownAP
2018-08-27Labeling · Supplement 12 · standardAP
2013-01-02Labeling · Supplement 8 · standardAP
2009-03-03Labeling · Supplement 3AP
2005-03-28OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →